Retatrutide 10mg provides the most popular research dose for the triple incretin agonist. With a ~6-day half-life and documented −28.7% body weight reduction in Phase 2 trials, this is the flagship weight-loss research compound in the Valerian catalogue.
- Triple receptor agonism — simultaneous GLP-1, GIP, and glucagon receptor activation.
- Highest recorded weight loss — −28.7% mean body weight at 48 weeks (Phase 2, NEJM).
- Increased energy expenditure — glucagon component drives thermogenesis and lipolysis.
- Hepatic lipid metabolism — reduces liver fat, ALT, AST, cholesterol, and triglycerides in research models.
⚠️ For research use only. Not for human or animal consumption. Store at −20°C. Reconstitute with Bacteriostatic Water.
Reviews
There are no reviews yet.